Three new distributor agreements build on initial China sales and extend the Company's distributor-led commercial strategyLONDON, Oct. 29, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX)
Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders' equity attributable to ordinary shareholders of $7.3 millionFosun Diagnostics agreement,
LONDON, July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX) today closed its previously announced exercise of certain outstanding preferred investment
DENVER, July 10, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government
LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of
LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an
LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that the board of directors of the Company approved a share consolidation of the
LONDON, May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test
Virax Biolabs is advancing a focused strategy centered on ViraxImmune™ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite its balance
LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO
Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA,
LONDON, Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and
Virax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a series of
LONDON, Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis
LONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune response detection and diagnostics, today
